Functional movement disorder (FMD) is a common source of neurological disability that imposes a significant financial burden on healthcare systems. However, the heterogeneous manifestations of FMD and numerous associated non-motor symptoms, often fluctuating over time, present a challenge for developing effective treatment pathways. Although increasing evidence supports the efficacy of physiotherapy for FMD, the lack of predictors of treatment outcomes remains a significant obstacle to effectively managing FMD. The main hypothesis of this project is that abnormalities in interoceptive processing are responsible for variability in motor and non-motor symptoms and response to physiotherapy. Interoception describes the afferent signalling, central processing, and mental representation of internal bodily signals. We hypothesize that worse performance on interoceptive tests will be associated with greater severity of motor and non-motor symptoms and worse quality of life. We also expect that patients with worse interoceptive performance and associated non-motor symptoms such as pain will particularly benefit from treatment techniques modulating interoception, such as specific breathing techniques. Therefore, to test our hypotheses, in this project, we will study interoceptive and attentional abnormalities of FMD and identify predictors of the effect of physiotherapy and interoceptive respiratory training.
Functional Neurological Disorder (FND) is a poorly understood and prevalent disorder, making up 16% of outpatient neurology referrals. Patients with functional movement disorder (FMD), which is one of the most common subtypes of FND, are difficult to treat. While growing evidence highlights the effectiveness of physiotherapy for FMD, the absence of reliable predictors for treatment outcomes remains a major challenge in managing the condition effectively. Our goal is to evaluate the interoceptive profile of individuals with FMD and establish a connection between interoceptive and attentional abnormalities, the type and severity of symptoms, and the response to treatment. The study will utilize the objective clinical and subjective evaluation of symptom severity along with behavioural, neurophysiological, and neuroimaging methods to provide a comprehensive set of measures of interoception and attention. fMRI will further elucidate the neural correlates of interoception and attention. These measures will be analyzed in a cohort of FMD patients and healthy controls to examine the relationship between interoception, attention, and the type, severity, and impact of motor and non-motor symptoms on quality of life. Interoceptive and attentional measures will also be tested as markers of therapy outcomes in a prospective randomized controlled trial. Eighty FMD patients will be recruited to undergo FMD-specific physiotherapy, with one group receiving additional interoception training via a specific breathing technique (SBTs) protocol. Participants will be randomized to physiotherapy alone or physiotherapy plus SBTs, with clinical outcomes, interoceptive, and attentional measures assessed before and after treatment. This design will evaluate the interventions' impact and identify treatment outcome predictors. Specific Aims Aim 1: To explore interoceptive mechanisms in FMD and their relationship to symptoms and treatment response. 1.1 Characterize interoceptive profiles (respiroceptive and cardioceptive sensitivity and metacognition) in FMD compared to healthy controls. 1.2 Investigate associations between interoception, motor symptoms, and pain. 1.3 Evaluate interoceptive sensitivity as a predictor of PT outcomes and the impact of SBTs on interoception and pain reduction. 1.4 Examine changes in interoceptive network activation (e.g., salience network) following PT, with or without SBTs. Aim 2: To study attentional mechanisms in FMD and identify predictors of PT outcomes. 2.1 Assess distractibility as a predictor of PT outcomes. 2.2 Evaluate attentional measures during cognitive, emotional and oculomotor tasks and their relationship to FMD symptoms and PT outcomes. 2.3 Investigate changes in brain activation related to attentional processing and symptom control. Aim 3: To evaluate the additive effects of specific breathing techniques (SBTs) on physiotherapy outcomes in FMD. 3.1 Compare outcomes between patients receiving PT alone and PT plus SBTs. 3.2 Assess whether SBTs enhance interoception and improve symptoms and HRQoL. Methods: Aim 1. Interoceptive sensitivity, metacognition, and attention will be evaluated using psychophysical tasks, fMRI, and eye-tracking to explore their relationship with symptoms and treatment outcomes in FMD. Aim 2: Attentional mechanisms, including distractibility, will be assessed through clinical tasks, neurophysiological recordings, and fMRI to identify predictors of physiotherapy outcomes. Aim 3: The effects of SBTs as an adjunct to physiotherapy will be evaluated using clinical scales for motor and non-motor symptoms, alongside quality-of-life and psychological measures.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
OTHER
Masking
SINGLE
Enrollment
80
The intervention will consist of 10 individual physiotherapy sessions delivered by a single physiotherapist trained in FMD. The physiotherapy programme will include education, movement retraining and a self-management plan.
The intervention will include education and training in specific breathing techniques, which will be exercised by the patient as a self-management plan for over 5-10 minutes daily.
General University Hospital in Prague
Prague, Czech Republic, Czechia
Clinical Global Impressions (CGI) scale - patient rated
Clinical Global Impressions (CGI-I) scale, patient-rated, is a 5-point scale evaluating improvement from 'very much improved' to 'very much worse'. 'Very much improved' indicates a better outcome.
Time frame: pre-treatment (baseline), one week after the last intervention, 6-month follow-up, 12-month follow-up
Clinical Global Impressions (CGI) - clinician rated scale
Adapted Patient Clinical Global Impression Improvement (CGI-I) scale rated by the outcome assessor is a 7-point scale of improvement from 'very much improved' to 'very much worse'. 'Very much improved' means a better outcome.
Time frame: one week after the last intervention, 6-month follow-up, 12-month follow-up
36-item Short Form Survey (SF-36)
The 36-item Short Form Health Survey (SF-36) is a self-report test assessing functional ability. Scores range from 0 to 100, with higher scores indicating better outcomes.
Time frame: pre-treatment (baseline), one week after the last intervention, 6-month follow-up, 12-month follow-up
Fibromyalgia Survey Questionnaire
The Widespread Pain Index (WPI) and Somatic Symptom (SS) score are evaluated using the Fibromyalgia Survey Questionnaire. The WPI score ranges from 0 to 19 and assesses the distribution of pain across the body, while SS scores evaluate the intensity of associated symptoms. Higher scores indicate a worse outcome.
Time frame: pre-treatment (baseline), one week after the last intervention, 6-month follow-up, 12-month follow-up
The Simplified Functional Movement Disorders Rating Scale (S-FMDRS)
The Simplified Functional Movement Disorders Rating Scale (S-FMDRS), a clinician-rated scale, assesses the severity of motor disorder symptoms across seven body regions. Scores range from 0 to 54, with higher scores indicating greater severity.
Time frame: pre-treatment (baseline), one week after the last intervention, 6-month follow-up, 12-month follow-up
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.